An IPO, In This Environment?
Motley Fool Money
00:00
Cautious Optimism in Alzheimer's Research
This chapter delves into Biogen's promising announcement regarding Lakenumab, an experimental Alzheimer's drug that shows potential in slowing disease progression. The speakers advocate for a careful and measured approach in response to the trial results, emphasizing the need for further validation and prudent investment strategies.
Play episode from 07:31
Transcript
